Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,728.50
Bid: 1,650.00
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 83.00 (5.03%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sunday newspaper round-up: Meggitt, GlaxoSmithKline, Luxury goods

Sun, 15th Aug 2021 17:08

(Sharecast News) - Ministers must be prepared to block a takeover of Meggitt if any bidder tries to buy it without giving binding commitments on investment and jobs, the FTSE 250 aerospace and defence manufacturer's chairman warned this weekend. Sir Nigel Rudd said that while "clearly, price is important", any new owner would need to give Meggitt and the government undertakings, including to keep the company's headquarters in Coventry and maintain R&D spending. - Sunday Times

A legal battle between Britain's two pharma champions has escalated after Glaxo Smith Kline launched a counter-claim against rival Astra Zeneca. It revolves around sales of Glaxo's top-selling cancer drug, Zejula, a treatment for ovarian and other cancers. Astra licenses the underlying technology to Glaxo, and claims it should receive a greater share of Zejula's sales. It accused Glaxo of breaching the terms of its agreement and has hired accountants KPMG to audit Zejula's sales. A source suggested the claim could reach hundreds of millions of pounds. - Sunday Times

The fortunes of the world's biggest luxury goods groups have been lifted by a splurge on expensive jewellery, watches, fashion and champagne as billions in spare cash is spent on big-budget treats. Sales at 11 of the largest luxury groups and their brands have grown by a fifth on average compared with 2019, before the pandemic began. And they have more than doubled on last year. - Financial Mail on Sunday

Talks to get the US investment giant Apollo on board to finance a bid to buy Morrisons have cooled after a shock increase in the offer price earlier this month. New York-based Apollo had been lined up to join a takeover consortium led by the private equity firm Fortress. But market sources this weekend said they believed Apollo had baulked at the dramatic £400 million price increase for the supermarket chain. - Financial Mail on Sunday

The magazine publisher behind The Week is on the verge of being sold to Future, the FTSE 250- listed media group. Future, which also owns Marie Claire and football magazine FourFourTwo, is in 'advanced' discussions with the private equity owners of Dennis Publishing about a takeover of a large number of the company's most well-known publications. - Financial Mail on Sunday

Imposing "premature austerity" again will undermine the fight against climate change and stop poorer households going green, one of the world's leading climate economists has warned the government, amid claims that the Treasury is resisting policies to tackle the crisis. Nicholas Stern, the author of the seminal 2006 government study into the costs of climate change, said comprehensive programmes were needed to help poorer households make the switch to electric cars and away from gas heating, if the government hoped to bring all greenhouse gas emissions to net zero by 2050. - Guardian

BT is threatening to crush competition and slow Britain's upgrade to faster full-fibre broadband by bringing in unfair prices, Virgin Media O2 has warned. The newly merged telecoms giant claims discounts being offered to broadband retailers buying access to the new network set a "dangerous precedent" that will scupper investment. - Sunday Telegraph

Amazon is adding own-brand groceries to its UK website to bolster its online offering, as the retail titan steps up its assault on British supermarkets. The business will allow shoppers to add hundreds of "By Amazon" and "Our Selection" products to their virtual baskets in the coming weeks. Bosses are expected to launch an advertising blitz to promote the ranges as they seek to attract more customers to its Fresh service, sources said. - Sunday Telegraph

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.